These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 18579379)
1. Daily salbutamol in young patients with SMA type II. Pane M; Staccioli S; Messina S; D'Amico A; Pelliccioni M; Mazzone ES; Cuttini M; Alfieri P; Battini R; Main M; Muntoni F; Bertini E; Villanova M; Mercuri E Neuromuscul Disord; 2008 Jul; 18(7):536-40. PubMed ID: 18579379 [TBL] [Abstract][Full Text] [Related]
2. Pilot trial of albuterol in spinal muscular atrophy. Kinali M; Mercuri E; Main M; De Biasia F; Karatza A; Higgins R; Banks LM; Manzur AY; Muntoni F Neurology; 2002 Aug; 59(4):609-10. PubMed ID: 12196659 [TBL] [Abstract][Full Text] [Related]
3. Salbutamol tolerability and efficacy in patients with spinal muscular atrophy type II. Frongia AL; Natera-de Benito D; Ortez C; Alarcón M; Borrás A; Medina J; Vigo M; Padrós N; Moya O; Armas J; Carrera-García L; Expósito-Escudero J; Cuadras D; Bernal S; Martorell L; Colomer J; Nascimento A Neuromuscul Disord; 2019 Jul; 29(7):517-524. PubMed ID: 31201046 [TBL] [Abstract][Full Text] [Related]
4. Pilot trial of phenylbutyrate in spinal muscular atrophy. Mercuri E; Bertini E; Messina S; Pelliccioni M; D'Amico A; Colitto F; Mirabella M; Tiziano FD; Vitali T; Angelozzi C; Kinali M; Main M; Brahe C Neuromuscul Disord; 2004 Feb; 14(2):130-5. PubMed ID: 14733959 [TBL] [Abstract][Full Text] [Related]
5. Drug treatment for spinal muscular atrophy types II and III. Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF Cochrane Database Syst Rev; 2020 Jan; 1(1):CD006282. PubMed ID: 32006461 [TBL] [Abstract][Full Text] [Related]
7. Pilot trial of salbutamol in central core and multi-minicore diseases. Messina S; Hartley L; Main M; Kinali M; Jungbluth H; Muntoni F; Mercuri E Neuropediatrics; 2004 Oct; 35(5):262-6. PubMed ID: 15534757 [TBL] [Abstract][Full Text] [Related]
8. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial). Stam M; Wadman RI; Wijngaarde CA; Bartels B; Asselman FL; Otto LAM; Goedee HS; Habets LE; de Groot JF; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL BMJ Open; 2018 Jul; 8(7):e019932. PubMed ID: 30061431 [TBL] [Abstract][Full Text] [Related]
9. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study. Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243 [TBL] [Abstract][Full Text] [Related]
10. Longitudinal evaluation of SMN levels as biomarker for spinal muscular atrophy: results of a phase IIb double-blind study of salbutamol. Tiziano FD; Lomastro R; Abiusi E; Pasanisi MB; Di Pietro L; Fiori S; Baranello G; Angelini C; Sorarù G; Gaiani A; Mongini T; Vercelli L; Mercuri E; Vasco G; Pane M; Vita G; Vita G; Messina S; Petillo R; Passamano L; Politano L; Campanella A; Mantegazza R; Morandi L J Med Genet; 2019 May; 56(5):293-300. PubMed ID: 30593463 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Bertini E; Dessaud E; Mercuri E; Muntoni F; Kirschner J; Reid C; Lusakowska A; Comi GP; Cuisset JM; Abitbol JL; Scherrer B; Ducray PS; Buchbjerg J; Vianna E; van der Pol WL; Vuillerot C; Blaettler T; Fontoura P; Lancet Neurol; 2017 Jul; 16(7):513-522. PubMed ID: 28460889 [TBL] [Abstract][Full Text] [Related]
12. Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen. Coratti G; Pane M; Lucibello S; Pera MC; Pasternak A; Montes J; Sansone VA; Duong T; Dunaway Young S; Messina S; D'Amico A; Civitello M; Glanzman AM; Bruno C; Salmin F; Tacchetti P; Carnicella S; Sframeli M; Antonaci L; Frongia AL; De Vivo DC; Darras BT; Day J; Bertini E; Muntoni F; Finkel R; Mercuri E; Neuromuscul Disord; 2021 Jul; 31(7):596-602. PubMed ID: 34099377 [TBL] [Abstract][Full Text] [Related]